Viking Therapeutics: Poised to Disrupt Obesity Drug Market

Viking Therapeutics weight-loss drug candidate, VK2735, is generating significant buzz on Wall Street, with a consensus price target of $93.59, representing a 170% increase from the current share price. VK2735, a dual agonist of GLP-one and GIP, is set to start phase three trials next quarter, following promising phase two results. The drug has shown potential in delivering up to 14.7% average weight loss in just 13 weeks, with better tolerability than competitors like Wegovy and Zepbound. Analysts predict a strong buy rating for Viking, anticipating positive phase three data next year, as the obesity drug market is expected to grow from $26 billion last year to over $130 billion by 2031. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/15b63455bc028a2b